2. Amyotrophic lateral sclerosis
508 clinical trials,   530 drugs   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03835507
(ClinicalTrials.gov)
June 20, 20168/8/2018Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral SclerosisRandomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: recombinant human erythropoietin(rhEPO)Hanyang University Seoul HospitalNULLRecruiting25 Years80 YearsAll64Phase 1;Phase 2Korea, Republic of
2EUCTR2011-001329-26-IT
(EUCTR)
03/08/201117/11/2011Erythropoietin in Amyotrophic Lateral Sclerosis: a study to identify the best dose and the optimal route of administration and evaluate the safetyErythroPOietin in ALS: a Study of dose-finding and Safety - EPOSS2010 Amyotrophic Lateral Sclerosis
MedDRA version: 14.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: EPREX*1SIR 40000UI/ML 1ML
INN or Proposed INN: ERYTHROPOIETIN
ISTITUTO NEUROLOGICO CARLO BESTANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Italy
3EUCTR2009-016066-91-IT
(EUCTR)
10/03/201017/11/2009SAFETY AND EFFICACY OF ERYTHROPOIETIN IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL - NDSAFETY AND EFFICACY OF ERYTHROPOIETIN IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL - ND ALS
MedDRA version: 9.1;Level: SOC;Classification code 10029205
Trade Name: EPREX*1SIR 40000UI/ML 1ML
INN or Proposed INN: Erythropoietin
ISTITUTO NEUROLOGICO CARLO BESTANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
4EUCTR2005-005873-31-IT
(EUCTR)
01/08/200514/03/2006A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of Erytropoietin administered by iv route as add-on treatment in patients affected by Amyotrophic Lateral Sclerosis ALS - NDA randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of Erytropoietin administered by iv route as add-on treatment in patients affected by Amyotrophic Lateral Sclerosis ALS - ND Amiotrophic Lateral Sclerosis
MedDRA version: 6.1;Level: PT;Classification code 10002026
Trade Name: EPREX IV SC 1FL 1ML 40000 UI
INN or Proposed INN: Erythropoietin
ISTITUTO NEUROLOGICO CARLO BESTANULLNot RecruitingFemale: yes
Male: yes
20Italy